The biomarker landscape in mycosis fungoides and Sézary syndrome

Brittany Dulmage; Larisa Geskin; Joan Guitart; Oleg E. Akilov

doi:10.1111/exd.13261

The biomarker landscape in mycosis fungoides and Sézary syndrome

Brittany Dulmage, Larisa Geskin, Joan Guitart, Oleg E. Akilov^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.

Original language	English (US)
Pages (from-to)	668-676
Number of pages	9
Journal	Experimental Dermatology
Volume	26
Issue number	8
DOIs	https://doi.org/10.1111/exd.13261
State	Published - Aug 2017

Keywords

cell surface marker
cutaneous T-cell lymphoma
gene expression
screening
secretory protein

ASJC Scopus subject areas

Dermatology
Molecular Biology
Biochemistry

Access to Document

10.1111/exd.13261

Cite this

@article{3204f45d3a8f4fae89f74de17de489be,

title = "The biomarker landscape in mycosis fungoides and S{\'e}zary syndrome",

abstract = "The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and S{\'e}zary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and S{\'e}zary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.",

keywords = "cell surface marker, cutaneous T-cell lymphoma, gene expression, screening, secretory protein",

author = "Brittany Dulmage and Larisa Geskin and Joan Guitart and Akilov, {Oleg E.}",

note = "Publisher Copyright: {\textcopyright} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2017",

month = aug,

doi = "10.1111/exd.13261",

language = "English (US)",

volume = "26",

pages = "668--676",

journal = "Experimental Dermatology",

issn = "0906-6705",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - The biomarker landscape in mycosis fungoides and Sézary syndrome

AU - Dulmage, Brittany

AU - Geskin, Larisa

AU - Guitart, Joan

AU - Akilov, Oleg E.

PY - 2017/8

Y1 - 2017/8

N2 - The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.

AB - The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.

KW - cell surface marker

KW - cutaneous T-cell lymphoma

KW - gene expression

KW - screening

KW - secretory protein

UR - http://www.scopus.com/inward/record.url?scp=85011684840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011684840&partnerID=8YFLogxK

U2 - 10.1111/exd.13261

DO - 10.1111/exd.13261

M3 - Review article

C2 - 27897325

AN - SCOPUS:85011684840

SN - 0906-6705

VL - 26

SP - 668

EP - 676

JO - Experimental Dermatology

JF - Experimental Dermatology

IS - 8

ER -

The biomarker landscape in mycosis fungoides and Sézary syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this